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Edited by Angel NebradaAbstract p110C, a 50-kDa isoform of the PITSLRE kinase
family, was demonstrated to play an important role in cell apop-
tosis. However, how p110C exactly promotes apoptosis is unclear.
Our previous study showed that p110C interacted with p21-acti-
vated kinase 1 (PAK1), an important kinase of the proapoptotic
BCL-2 family member BAD, and evidently inhibited its kinase
activity. Here, we report that overexpression of p110C leads to
decreased phosphorylation of BAD and its subsequent transloca-
tion from cytosol to mitochondria, which in turn induces the re-
lease of cytochrome c and the onset of apoptosis. Knocking
down endogenous BAD expression will inhibit p110C induced
apoptosis. Two kinase dead forms of p110C, D149N and K36N,
lose the ability to inhibit the kinase activity of PAK1 and fail to
induce the translocation of BAD and the BAD and such proapop-
totic ability is associated with the kinase activity of p110C.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Apoptosis is a distinct form of cell death to keep the cellular
homeostasis carried out by a genetically determined cell suicide
program [1,2]. Among the apoptosis regulators, the BCL-2
protein family members are well studied [3]. The members
can either promote survival (BCL-2, BCL-XL) or induce cell
death (BAD, BAX and BAK) [4,5]. It has been suggested that
the ratio between these two subsets helps to determine the sus-
ceptibility of cells to death signals [5]. BAD belongs to the so
called BH3-only proteins subset and all of them are proapop-
totic [6]. The function of BAD is regulated primarily by rapid
changes of its phosphorylation state that modulates its pro-
tein–protein interactions and subcellular localization [7]. To
date, several kinases have been shown to phosphorylate
BAD including p21-activated kinase 1 (PAK1) which phos-
phorylates BAD on Ser112 and Ser136 [7–10]. Recently some
other BAD residues (Ser155 and Ser170) were identiﬁed as
apoptosis related phosphorylation sites [11,12]. When BAD*Corresponding author. Fax: +86 21 64164489.
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doi:10.1016/j.febslet.2005.12.097is unphosphorylated, it binds to anti-apoptotic partners
BCL-2 or BCL-XL, which inhibits them to block the release
of cytochrome c from mitochondria, a critical step in the acti-
vation of the downstream caspase protease cascade [13,14].
When BAD is phosphorylated on one or more of these serine
residues in response to survival factors, it dissociates from
complexes with BCL-XL and subsequently interacts with cyto-
solic adaptor protein 14-3-3s. The uncomplexed BCL-XL is
then able to suppress cell death by blocking mitochondrial
cytochrome c release [8].
The PITSLRE protein kinases are parts of the large family
of p34cdc2-related kinases [15,16]. Studies showed that several
PITSLRE kinase isoforms might serve as eﬀectors in apoptotic
signaling pathways and their kinase activity was critical for
apoptosis induction [17,18]. Previous studies found that apop-
tosis was increased when p110C, a processed PITSLRE iso-
form produced by proteolysis of larger isoforms, was
ectopically expressed in Chinese hamster ovary cells or SMMC
7721 hepatocarcinoma cells [17,19]. To further study the cellu-
lar functions of p110C, Chen et al. used p110C as bait to
screen a human fetal liver cDNA library and identiﬁed p21-
activated kinase 1 (PAK1) as a p110C associated protein.
The overexpression of p110C increased anoikis of NIH3T3
cells and PAK1 activity was signiﬁcantly inhibited [20]. How-
ever, the down stream events of p110C–PAK1 interaction and
the mechanism by which the kinase activity of PITSLRE fam-
ily members induced apoptosis remain unclear. Here, we re-
port that the inhibited PAK1 kinase activity resulting from
p110C overexpression led to reduced phosphorylation state
of BAD Ser112 and Ser136 and its translocation to mitochon-
dria, which in turn induced the release of cytochrome c and
triggered apoptosis. The eﬀects of p110C on PAK1 and its
apoptosis inducing function were closely related to its kinase
activity. The two kinase dead forms of p110C could not inhibit
PAK1 activity or induce BAD translocation. These results
linked p110C to BCL-2 family member BAD through the
mediation of PAK1 and showed the association of p110C ki-
nase activity with apoptosis. This further explained the
involvement of p110C in apoptotic signaling pathways.2. Materials and methods
2.1. Cell culture
NIH3T3 cells, HeLa cells, and SMMC 7721 hepatocarcinoma cells
were obtained from the Institute of Cell Biology Academic Sinica
and grown in DMEM supplemented with 10% fetal bovine serum
and 1% penicillin/streptomycin at 37 C in 5% CO2.blished by Elsevier B.V. All rights reserved.
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Protein G–agarose and anti-HA (12CA5) antibody were purchased
from Roche Applied Science. [c-32P] ATP (>3000 Ci/mM) and ECL as-
say kit were products of Amersham Biosciences. Leupeptin, aprotinin,
PMSF, poly-HEME, myelin basic protein (MBP) and histone H1 were
purchased from Sigma. Antibodies against b-actin, PITSLRE, PAK1
and PAK2 were from Santa Cruz Biotechnology. Antibody against
PAK3 was from Calbiochem. Antibodies against Myc and COX IV,
the vector pcDNA3, Lipofect AMINE and Lipofectamine2000 re-
agents were from Invitrogen. Antibodies against BAD, phosphoSer112,
and phosphoSer136 of BAD were from Oncogene. Rabbit polyclonal
anti-PKB, anti-phosphoSer308, anti-phosphoSer473 of PKB and
anti-phosphoSer155 of BAD antibodies were from Cell Signalling.
TheMutanBEST kit was bought from Takara. Z-VAD-FMKwas from
R&D Company. Other reagents were commercially available in China.
2.3. Plasmids and siRNA sequences
The plasmid of antisense-PAK1 was constructed by inverting and
inserting cDNA sequence fragment (nt 1–996) of PAK1 into pcDNA3.
The cDNA sequence encoding aa 210–332 of PAK1 was inserted into
pcDNA3.1/Myc-His()A to construct the PAK1 deletion mutant
PAK1m. The p110C kinase dead mutants K36N and D149N were con-
structed with the MutanBEST kit (Takara), using pcDNA3–HA-
p110C as template. The oligodeoxynucleotides primers used were:
5 0-GTGGCTCTAAACCGGCTGAAC-3 0 and 5 0-AAGGTGGGTA-
ACTT CGGGCTG-3 0. siRNA sequence for human BAD 5 0-AA-
GAAGGGACTTCCTCGCCCG-3 0 [21] and the negative control
sequence (Cat No. 4605) were synthesized by Ambion.
2.4. Apoptosis and isolation of subcellular fractions
Anoikis was performed as described [20]. Brieﬂy, NIH3T3 cells were
seeded in 3 · 106 cells/100-mm tissue culture dish. After culturing for
6 h, the medium was changed to serum-free DMEM. Following a fur-
ther culturing for 18 h, the cells were trypsinized and plated in cell sus-
pension dishes previously coated with 10 mg/ml poly-HEMA. After
the indicated period of time, the cells were collected for further inves-
tigation. Apoptosis was evaluated by FACScan ﬂow cytometer. The
percentage of apoptosis was quantitated from sub-G1 events. The
cytosol and mitochondrial fractions were isolated as described [22].
2.5. Immunoprecipitation and immunoblot assays
Forty-eight hours after transfection, cells were washed three times
with ice-cold PBS and solubilized with 1 ml of lysis buﬀer (50 mM
Tris–HCl, pH 7.5, 150 mM NaCl, 0.1% Nonidet P-40, 5 mM EDTA,
5 mM EGTA, 15 mMMgCl2, 60 mM b-glycerophosphate, 0.1 mM so-
dium orthovanadate, 0.1 mM NaF, 0.1 mM benzamide, 10 lg/ml
aprotinin, 10 lg/ml leupeptin and 1 mM PMSF). Detergent-insoluble
materials were removed by centrifugation at 13000 rpm for 15 min
at 4 C. The whole cell lysates were incubated with mouse normal
IgG (Santa Cruz Biotechnology) or relevant antibody at 4 C for
2 h. Pre-equilibrated protein G–agarose beads (Roche Applied Sci-
ence) were then added and collected by centrifugation after 2 h of incu-
bation and then gently washed three times with the lysis buﬀer. The
bound proteins were eluted by boiling in SDS sample buﬀer and re-
solved on a 12% SDS–PAGE gel. The proteins were transferred onto
a PVDF membrane and probed with a 1:1000 dilution of the relevant
antibodies. Then the proteins were detected using the ECL assay kit.
2.6. Kinase assay
As described by Chen et al. [20], the cells were washed twice with ice-
cold PBS, and lysed at 4 C in lysis buﬀer (50 mM Tris–HCl (pH 7.5),
150 mM NaCl, 0.1% Nonidet P-40, 5 mM EDTA, 5 mM EGTA,
15 mMMgCl2, 60 mM b-glycerophosphate, 0.1 mM sodium orthovan-
adate, 0.1 mM NaF, 0.1 mM benzamide, 10 lg/ml aprotinin, 10 lg/ml
leupeptin and 1 mM PMSF). Equal total protein was immunoprecipi-
tated with rabbit polyclonal anti-PAK1 (1:50) antibody at 4 C over-
night. Immune complexes were covered by adding protein G beads
and then centrifuged. The beads were washed twice in lysis buﬀer
and twice in kinase buﬀer (100 mM NaCl, 50 mM Tris (pH 7.5),
10 mM MgCl2 and 1 mM MnCl2). Kinase assays were performed in
50 ll reactions with 50 mM ATP, 10 lCi of [32P] ATP, and 5 lg of
MBP. After 30 min at 30 C, the reactions were terminated by the
addition of 10 ll of 6· sample buﬀer, boiled, separated by 15%
SDS–PAGE, and analyzed using autoradiography.3. Results
3.1. p110C Decreased the phosphorylation level of BAD on
Ser112 and Ser136
Our previous work showed that overexpression of p110C
inhibited kinase activity of PAK1 [20], and phosphorylated
BAD on Ser112 and Ser136 [9]. We intended to ﬁnd out
whether p110C overexpression could decrease BAD phosphor-
ylation. First we reconﬁrmed that overexpression of p110C did
inhibit PAK1 kinase activity. NIH3T3 cells were transiently
transfected with pcDNA3–HA or diﬀerent amounts of
pcDNA3–HA–p110C. Then whole cell lysates of each sample
containing equal total proteins were immunoprecipitated with
an anti-PAK1 antibody and assayed for PAK1 kinase activity,
using MBP as its substrate. As shown in Fig. 1A, the kinase
activity of endogenous PAK1 was markedly inhibited with
the introduction of p110C. Then NIH3T3 cells were transfec-
ted with diﬀerent amounts of pcDNA3–HA–p110C plasmid.
The cells were collected and phosphorylation of endogenous
BAD Ser112 and Ser136 was detected. It was found that while
there was a basal level of phosphorylated Ser112 and Ser136
and the transient transfection of p110C signiﬁcantly depressed
BAD phosphorylation level in a dose dependent manner, there
was no evident change in the BAD protein level (Fig. 1B, left
panel). The phosphorylation of Ser155, a site not phosphory-
lated by PAK1, was also tested. And overexpression of
p110C had no eﬀects on Ser155 phosphorylation at all. The
experiment was also repeated with SMMC 7721 hepatocarci-
noma cells and similar results were obtained (Fig. 1B, right pa-
nel). The results in Fig. 1 suggested that p110C aﬀected BAD
phosphorylation through inhibiting PAK1 kinase activity.
3.2. p110C aﬀected BAD subcellular localization and increased
apoptosis
Previous studies established that dephosphorylation of BAD
would lead to its binding to BCL-2 or BCL-XL, which inhibited
the ability of BCL-2 and BCL-XL to block the release of cyto-
chrome c frommitochondria, a critical step in inducing apopto-
sis [14]. To test whether p110C induces apoptosis by decreasing
the phosphorylation level of BAD and leading to its transloca-
tion from cytosol to mitochondria, we transiently expressed
p110C in NIH3T3 cells with pcDNA3–HA as control. Then
the cytosol and mitochondrial fractions were isolated as de-
scribed [22] and the cytosol and mitochondrial protein levels
of BAD were detected. As expected, overexpression of p110C
evidently induced BAD translocation from cytosol to mito-
chondria (Fig. 2A). Since inhibiting kinase activity of PAK1
otherwise would produce the same eﬀects as that of p110C,
we constructed an antisense-PAK1 plasmid to lower the expres-
sion level of endogenous PAK1. It was found that the transfec-
tion of the plasmid did reduce PAK1 expression and lead to
BAD translocation to mitochondria, while the expression of
PAK2 and PAK3 was not changed (Fig. 2A). We further ex-
plored whether cytochrome c was released after the transient
expression of p110C. It was found that both the overexpression
of p110C and the transfection of the antisense-PAK1 plasmid
signiﬁcantly induced cytochrome c release to cytosol
(Fig. 2B). We further studied whether the introduction of
p110C could make cells more responsive to death signals. Since
cycloheximide could induce cell death well and p58PITSLRE
could enhance cycloheximide induced apoptosis as demon-
strated in our previous work [19]. We transfected SMMC
Fig. 1. P110C decreased the phosphorylation level of BAD on Ser112 and Ser136. (A) NIH3T3 cells were grown on 60-mm tissue culture dishes. The
cells were transiently transfected with pcDNA3–HA or diﬀerent amounts of pcDNA3–HA–p110C (1 or 2 lg). Then whole cell lysates of each sample
containing equal total proteins were immunoprecipitated with an anti-PAK1 antibody and assayed for PAK1 kinase activity, using MBP as its
substrate. The lower band showed that the amount of PAK1 used in the reaction as constant, as assayed by Western blot analysis. (B) NIH3T3 cells
(left panel) or SMMC 7721 hepatocarcinoma cells (right panel) were transfected with 1, 2 or 3 lg of pcDNA3–HA–p110C plasmid for 48 h. The cells
were gathered and phosphorylation of Ser112, Ser136 and Ser155 of endogenous BAD was detected with the corresponding antibodies. The
endogenous protein level of BAD and transient expression of HA–p110C were also detected. b-Tubulin was used as internal standard to show equal
loading. The ﬁgure was representative of three independent experiments performed.
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HA–p110C or antisense-PAK1 plasmid. Twenty-four hours
after transfection, the cells were treated with cycloheximide
for 12 h, and then collected and analyzed with FACScan ﬂow
cytometer to detect apoptotic cells. Only about 12% cells were
apoptotic after the treatment of cycloheximide alone, while
overexpression of p110Cmarkedly increased apoptosis induced
by cycloheximide (about 31%), and reducing PAK1 expression
also increased apoptosis to a similar level (Fig. 2C). To ﬁnd out
if BAD was really required for p110C induced apoptosis, we
used RNA interference technology to knock down the BAD
expression [21]. SMMC 7721 hepatocarcinoma cells were trans-
fected with pcDNA3–HA or pcDNA3–HA–p110C alone or in
combination with siRNA sequence (250 nM) for BAD or nega-
tive control sequence. Twenty-four hours after transfection, the
cells were treated with cycloheximide (5 lg/ml) for 12 h and
then gathered and analyzed with FACScan ﬂow cytometer to
detect the apoptotic cells. It was interesting that BAD siRNA
sequence evidently reduced cycloheximide induced apoptosis
of p110C group, while the control sequence had no eﬀect on
BAD expression or apoptosis (Fig. 2D). These results suggested
that apoptosis induced by p110C requires mitochondrial trans-
location of BAD.
3.3. p110C induced BAD translocation and apoptosis through
inhibiting PAK1 activity
To rule out the possibility of the involvement of other
BAD regulators in p110C mediated apoptotic signaling path-
way [8,10,23], we constructed the PAK1 deletion mutant aa
210–332 (hereafter referred to as PAK1m for convenience)
into pcDNA3.1/Myc-His()A. Since it was found thatPAK1m could interact with p110C and the binding aﬃnity
was even higher than that of full length PAK1 [20], with a
loss of about 80% of the catalytic domain of PAK1, we could
co-express this mutant with p110C to block the interaction of
p110C with endogenous PAK1 without aﬀecting on the cells.
First we studied that if the introduction of PAK1m was able
to block p110C–PAK1 interaction. HA–p110C was tran-
siently expressed alone or in combination with PAK1m in
NIH3T3 cells. The whole cell lysates with equal amount of
proteins were immunoprecipitated with anti-HA monoclonal
antibody, followed by immunoblot analysis using an anti-
PAK1 antibody. Fig. 3A suggested that PAK1 was co-immu-
noprecipitated with HA–p110C and the co-expressed PAK1m
evidently blocked this interaction. Kinase assay showed that
while HA–p110C evidently inhibited PAK1 kinase activity,
the co-expression of PAK1m restored PAK1 activity
(Fig. 3B). This showed that PAK1m eﬀectively prevented
p110C from binding PAK1 and inhibiting its activity. We
then overexpressed p110C alone and in combination with
PAK1m in NIH3T3 cells and isolated the cytosol and mito-
chondrial fractions. It was found that when p110C was co-ex-
pressed with PAK1m, its potential to induce BAD
translocation to mitochondria and cytochrome c release was
evidently inhibited (Fig. 3C and D), whereas overexpressing
PAK1m alone had no eﬀect on BAD translocation or cyto-
chrome c release (data not shown). p110C no longer remark-
ably increased apoptosis induced by cycloheximide in SMMC
7721 hepatocarcinoma cells with the presence of PAK1m
(Fig. 3E). We next overexpressed p110C alone or in combina-
tion with PAK1m in NIH3T3 cells for 48 h, and then per-
forming Hoechst staining of nuclei. It was found that cells
Fig. 2. P110C aﬀected BAD subcellular localization and increased apoptosis. (A,B) p110C, antisense-PAK1 plasmid or empty vector were transiently
transfected into NIH3T3 cells. Then the cytosolic and mitochondrial fractions were isolated and protein levels of BAD (A) and cytochrome c (B)
were detected. COX IV, a protein speciﬁcally expressed in mitochondria, was used as internal standard for mitochondria parts. GAPDH was also
detected as loading control for cytosol parts. Endogenous PAK1, 2, and 3 levels were detected to show the eﬃciency and speciﬁcity of the antisense-
PAK1 plasmid, and p110C transfection was also detected (A). (C) SMMC 7721 hepatocarcinoma cells were transfected with pcDNA3–HA,
pcDNA3–HA–p110C or antisense-PAK1 plasmid. Twenty-four hours after transfection the cells were treated with cycloheximide (5 lg/ml) for 12 h,
then the cells were gathered and analyzed with FACScan ﬂow cytometer to detect the apoptotic rate. The error bars indicate ±S.E. of values pooled
from three independent experiments. (D) SMMC 7721 hepatocarcinoma cells were transfected with pcDNA3–HA or pcDNA3–HA–p110C alone or
in combination with siRNA sequence (250 nM) for BAD or negative control sequence (Neg). Twenty-four hours after transfection the cells were
treated with cycloheximide (5 lg/ml) for 12 h, then the cells were gathered and analyzed with FACScan ﬂow cytometer to detect the apoptosis. The
error bars indicate ±S.E. of values pooled from three independent experiments. The endogenous BAD and actin expression and also transfected
p110C were detected by Western blot.
816 C. Chen et al. / FEBS Letters 580 (2006) 813–821
Fig. 3. P110C induced BAD translocation and apoptosis through inhibiting PAK1 activity. (A) The whole cell lysates with equal amount of proteins
were immunoprecipitated with anti-HA monoclonal antibody, followed by immunoblot analysis using an anti-PAK1 antibody. The lower bands
showed the equal amount of total protein used and p110C transfection. (B) HA–p110C was transiently expressed alone or in combination with
PAK1m in NIH3T3 cells. Whole cell lysates of each sample containing equal total proteins were immunoprecipitated with an anti-PAK1 antibody
and assayed for PAK1 kinase activity. The phosphorylated MBPs were quantiﬁed using a densitometer and expressed as a percentage of the mock
group. The MBP phosphorylation density of the mock group was arbitrarily deﬁned as 100%. (C,D) p110C was overexpressed alone or in
combination with PAK1m in NIH3T3 cells and the cytosolic and mitochondrial fractions were isolated. Protein levels of BAD (C) and cytochrome c
(D) were detected using corresponding antibodies. (E) SMMC 7721 hepatocarcinoma cells were transfected with p110C alone or in combination with
PAK1m. Twenty-four hours after transfection the cells were treated with cycloheximide (5 lg/ml) for 12 h, then the cells were gathered and analyzed
with FACScan ﬂow cytometer to detect the apoptotic rate. The error bars indicate ±S.E. of values pooled from three independent experiments. (F)
3 lg of p110C were overexpressed alone with or without 50 lM Z-VAD-FMK treatment or in combination with PAK1m in NIH3T3 cells for 48 h,
and then Hoechst staining of nuclei was conducted. The transfected p110C and actin expression were detected by Western blot. (G) Anoikis in
NIH3T3 cells was induced for the indicated times shown by detachment from the cell matrix, and then mitochondrial fractions were isolated.
Mitochondrial BAD protein level and induced expression of p110C were detected using corresponding antibodies. PAK1 kinase assay was also
conducted as described in Fig. 1A.
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fragmented and condensed nuclei, and PAK1m co-expression
prevented the cells from apoptosis (Fig. 3F). Twenty-hour-treatment of the pancaspase inhibitor Z-VAD-FMK, which
inhibited the overall caspase activity, also prevented the cells
expressing p110C alone from undergoing apoptosis (Fig. 3F).
Fig. 4. The eﬀect of p110C on PAK1 was highly dependent on its
kinase activity. (A) HA–p110C, HA–K36N or HA–D149N was
transiently expressed in NIH3T3 cells. Then whole cell lysates of each
sample containing equal total proteins were immunoprecipitated with
an anti-HA antibody and assayed for p110C kinase activity, using
histone H1 as its substrate. The precipitated p110C proteins were
detected with anti-HA antibody. The ﬁgure was representative of three
independent experiments performed. (B) HA–p110C, HA–K36N or
HA–D149N was transiently expressed in NIH3T3 cells and the cell
lysates were immunoprecipitated with the anti-PAK1 antibody and
assayed for PAK1 activity. (C) HeLa cells were transfected with
pcDNA3.1 alone or treated with Wortmannin at 100 nM for 12 h and
wild-type or kinase dead forms of p110C for 48 h. The cells were
gathered and the PKB protein, Thr308 and Ser473 phosphorylation
levels were detected with the corresponding antibodies. b-Actin was
used as internal standard to show the constant protein amount loaded.
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induced during anoikis through processing of speciﬁc larger
PITSLRE isoforms [20], so we thought that BAD should also
be translocated to mitochondria during anoikis. Anoikis in
NIH3T3 cells was induced for the indicated time shown in
Fig. 3G by detachment from the cell matrix, and then mito-
chondrial fractions were isolated. Western blot analysis using
anti-PITSLRE antibody showed that p110C was induced dur-
ing anoikis, and mitochondrial BAD protein level was signiﬁ-
cantly enhanced with the appearance of p110C (Fig. 3G).
PAK1 kinase assay revealed that with the induction of
p110C, the kinase activity of PAK1 was greatly inhibited,
although the protein level of PAK1 remained constant during
anoikis (Fig. 3G).
3.4. The eﬀects of p110C on PAK1 was highly dependent on its
kinase activity
Having conﬁrmed that p110C induced BAD translocation
and apoptosis through inhibiting PAK1 kinase activity, we
proceeded to ﬁnd why p110C inhibited PAK1 kinase activity.
It was previously reported that the kinase activity of PITS-
LRE proteins was associated with apoptosis [17], so it was
important to ﬁnd out whether the kinase activity of p110C
was related to its eﬀect on PAK1. Two point mutation forms
of p110C, K36N and D149N were constructed according to
the corresponding kinase dead sites of p58PITSLRE [17]. To
ﬁnd out whether these mutants were really kinase dead,
HA–p110C, HA–K36N or HA–D149N was transiently ex-
pressed in NIH3T3 cells. Then whole cell lysates of each sam-
ple containing equal total proteins were immunoprecipitated
with an anti-HA antibody and assayed for p110C kinase
activity, using histone H1 as its substrate. As shown in
Fig. 4A, though wild-type p110C evidently phosphorylated
H1, both of the mutants failed to phosphorylate the sub-
strate, which suggested that the two mutants were really ki-
nase dead. In order to explore whether the two mutants
could also inhibit the kinase activity of PAK1 like wild-type
p110C, HA–p110C, HA–K36N or HA–D149N was tran-
siently expressed in NIH3T3 cells and the cell lysates were
immunoprecipitated with the anti-PAK1 antibody and as-
sayed for PAK1 activity. It was interesting that neither of
the kinase dead mutants could signiﬁcantly inhibit PAK1 ki-
nase activity (Fig. 4B), which suggested that the eﬀect of
p110C on PAK1 was to a great extend dependent on its ki-
nase activity. The involvement of p110C kinase activity in
its eﬀect on PAK1 suggested that p110C might inhibit
PAK1 kinase activity through phosphorylating it.
Akt/PKB mediated a major cell survival pathway through
phosphorylation of BAD kinase on Ser136 [8]. PKB was acti-
vated when its Thr308 and Ser473 were phosphorylated
[24,25]. In order to ﬁnd out whether the overexpression of
p110C would aﬀect the activity of PKB, HeLa cells were trans-
fected with wild-type p110C or two kinase dead forms K36N
and D149N. We found that p110C had no eﬀect on the protein
level or phosphorylation level on Thr308 and Ser473 of PKB
(Fig. 4C), while treatment of Wortmannin, a well known
PI3K/PKB pathway inhibitor, signiﬁcantly decreased PKB
phosphorylation. The data indicated that PKB was not in-
volved in the proapoptotic function of p110C. All these results
strongly suggested that p110C induced BAD translocation,
cytochrome c release and subsequent apoptosis directly
through inhibiting the kinase activity of PAK1.3.5. The eﬀects of p110C on BAD translocation and the close
relation between its kinase activity and apoptosis
As p110C induced BAD translocation and apoptosis
through inhibiting PAK1 kinase activity (Fig. 3) and the eﬀects
of p110C on PAK1 was highly dependent on its kinase activity
(Fig. 4), the kinase dead mutants of p110C should have lost the
potential to induce BAD translocation and apoptosis. To test
this inference, we transiently expressed wild-type p110C or
D149 mutant in NIH3T3 cells and the cytosolic and mitochon-
drial fractions were isolated. We found that loss of the kinase
activity resulted in the disability of p110C to induce BAD
translocation (Fig. 5A). To test whether p110C kinase dead
mutants could induce cytochrome c release, we transiently ex-
pressed wild-type p110C or K36N mutant in NIH3T3 cells and
detected cytochrome c in cytosolic and mitochondria fractions.
Fig. 5B showed that the potential of p110C to induce the re-
lease of cytochrome c from mitochondria was greatly inhibited
when p110C lost its kinase activity. D149N mutant was also
tested in the same way and a similar result was obtained
(data not shown). Finally we studied the ability of kinase dead
Fig. 5. The eﬀects of p110C on BAD translocation and to induce apoptosis were close related to its kinase activity. (A) Wild-type p110C or D149
mutant were transiently expressed in NIH3T3 cells. BAD expression of cytosolic and mitochondrial fractions was detected. (B) Wild-type p110C and
K36N mutant were transiently expressed in NIH3T3 cells. Cytochrome c expression in cytosolic and mitochondrial fractions was detected. (C)
Diﬀerent amounts of pcDNA3–HA–p110C or pcDNA3–HA–D149N were transfected to NIH3T3 cells. Twenty-four hours after the transfection,
anoikis was induced for 4 h and the cells were analyzed with FACScan ﬂow cytometer to detect the apoptosis rate. The error bars indicated ±S.E. of
values pooled from three independent experiments. The transfected p110C and actin expression were detected by Western blot.
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pcDNA3–HA–p110C or pcDNA3–HA–D149N was transfec-
ted into NIH3T3 cells. Twenty-four hours after the transfec-
tion, anoikis was induced for 4 h and the cells were analyzed
with a FACScan ﬂow cytometer to detect apoptosis. Com-
pared to wild-type p110C, D149N increased NIH3T3 cells
apoptosis much less drastically (Fig. 5C). All these results
strongly suggested that the kinase activity of p110C was closely
related to its apoptosis inducing function.4. Discussion
In this report, we demonstrated that the overexpression of
p110C inhibited BAD phosphorylation on Ser112 and
Ser136 and led to its subsequent translocation from cytosol
to mitochondria, which in turn induced the release of cyto-
chrome c from mitochondria and the onset of apoptosis. These
eﬀects of p110C were observed after speciﬁcally inhibiting theactivity of PAK1, a BAD kinase. Kinase dead forms of p110C
could not inhibit the kinase activity of PAK1 and could no
longer induce BAD translocation or apoptosis. The data sug-
gested that apoptosis inducing potential of p110C was associ-
ated with its kinase activity.
The p21-activated kinases (PAKs) were members of RAC/
CDC42-associated Ser/Thr protein kinases. Based on their con-
served structure, the six known PAKs were classiﬁed as Group I
PAKs (PAK1–3) and Group II PAKs (PAK4–6) [26]. The ki-
nase activity of PAK1 and PAK5 was found to be related to
their activity of protecting cells from apoptosis [9,10]. In our
previous study, p110C was revealed to interact with PAK1
and greatly inhibit its kinase activity [20]. P110C did not weak-
en the interaction of PAK1 with its upstream constitutive active
activator CDC42V12, nor could p110C aﬀect the basal phos-
phorylation level of Thr423, an important PAK1 activation le-
vel indicator [9] (data not shown). These results suggested that
p110C inhibited PAK1’s kinase activity in some unknownman-
ners. Then we found that the eﬀects of p110C on PAK1 was
820 C. Chen et al. / FEBS Letters 580 (2006) 813–821highly dependent on its kinase activity (Fig. 4). The two p110C
kinase dead forms, K36N and D149N, all failed to inhibit the
kinase activity of PAK1 (Fig. 4B). Given all these results, we
concluded that instead of aﬀecting the activation of CDC42,
RAC or other kinases on PAK1, p110Cmight inhibit PAK1 ki-
nase activity in other ways related to its kinase activity. For in-
stance, p110C might phosphorylate some unidentiﬁed sites of
PAK1 N-terminal regulatory domain (RD), which kept RD
binding to its kinase domain to block PAK1 kinase activity.
Being the proapoptotic member of BCL-2 family, BAD
translocated between cytosol and mitochondrial membrane
based partners BCL-2 or BCL-XL [10]. Instead of inducing
apoptosis directly as BAX, BAD interacted with BCL-2 and
BCL-XL to inhibit their ability to block the release of cyto-
chrome c from mitochondria [9]. PAK1 was found to phos-
phorylate BAD in vitro and in vivo [9]. This should prevent
BAD’s translocation to mitochondria to induce apoptosis.
We found that p110C induced apoptosis, at least in part,
through leading to BAD translocation to mitochondria and
cytochrome c release to cytosol (Fig. 2). The apoptosis induc-
ing ability of p110C was closely related to its eﬀects on PAK1.
A PAK1 deletion mutant PAK1m (aa 210–332) which eﬀec-
tively blocked p110C–PAK1 interaction evidently inhibited
BAD translocation and apoptosis induced by p110C
(Fig. 3A–F). These results showed that p110C, PAK1 and
BAD were linked and had important physiological eﬀects on
in apoptosis events.
In consideration of these results as well as our previous ﬁnd-
ings, we concluded that upon receiving some death signals,
some speciﬁc larger PITSLRE protein kinases were cleaved
by caspases to produce p110C. P110C then bound to PAK1
to inhibit its kinase activity, in which the kinase activity of
p110C played some key roles (although the relation of
p110C kinase activity to its eﬀect on PAK1 was not clear).
The phosphorylation of BAD by PAK1 was greatly inhibited
accordingly, which led to its translocation to mitochondria
to induce the releasing of cytochrome c, which in turn further
activated caspases to induce apoptosis. But the K36N mutant
still led to cytochrome c release (Fig. 5B). Compared to the
empty vector, the D149 mutant increased anoikis of NIH3T3
cells (Fig. 5C). These results suggested that p110C might in-
duce apoptosis in some other unknown ways.
In summary, we demonstrated in this report that p110C in-
duced apoptosis through leading to subcellular translocation
of BAD, which was mediated by the inhibitive eﬀect of
p110C on the kinase activity of PAK1. This eﬀect was greatly
dependent on its kinase activity. By showing the mechanism by
which p110C was involved in apoptotic signaling pathway and
explaining why its kinase activity was associated with apopto-
sis, our study provided new clues to the understanding of p110
mediated apoptosis.
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